{"title":"Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC","authors":"","doi":"10.1056/nejmc2411471","DOIUrl":null,"url":null,"abstract":"To the Editor: The trial by Lu et al. (Aug. 15 issue)1 showed a significant progression-free survival benefit with osimertinib in patients with stage III non–small-cell lung cancer (NSCLC) with an ...","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":96.2000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"New England Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1056/nejmc2411471","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
To the Editor: The trial by Lu et al. (Aug. 15 issue)1 showed a significant progression-free survival benefit with osimertinib in patients with stage III non–small-cell lung cancer (NSCLC) with an ...
期刊介绍:
The New England Journal of Medicine (NEJM) stands as the foremost medical journal and website worldwide. With an impressive history spanning over two centuries, NEJM boasts a consistent publication of superb, peer-reviewed research and engaging clinical content. Our primary objective revolves around delivering high-caliber information and findings at the juncture of biomedical science and clinical practice. We strive to present this knowledge in formats that are not only comprehensible but also hold practical value, effectively influencing healthcare practices and ultimately enhancing patient outcomes.